sars cov 2 — grants

Sort

8,912 grants matching “sars cov 2”

Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors

$759,344

Julio Alonso Chirinos Medina · University Of Pennsylvania · R01 · FY2024 · HL

Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses

$759,331

Lanying Du · Georgia State University · R01 · FY2025 · AI

Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses

$759,331

Lanying Du · Georgia State University · R01 · FY2023 · AI

REstoring mental health after COVID-19 through commUnity-based Psychological services in New York City (RECOUP-NY)

$759,241

Brandon Alan Kohrt · George Washington University · R01 · FY2022 · MH

Immune response to COVID-19 vaccine in HIV infected men and women

$758,692

Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AI

COVID-19 Mother Baby Outcomes (COMBO): brain-behavior functioning

$758,606

Dani Dumitriu · Columbia University Health Sciences · R01 · FY2025 · MH

Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm

$758,444

Jeffrey S Glenn · Stanford University · R01 · FY2023 · AI

Discovering Affective Drug Combinations for Treating Covid-19

$758,271

Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Immunological drivers of the transition from epidemicity to endemicity of SARS-CoV-2 in a high transmission LMIC setting

$758,022

Albert Icksang Ko · Yale University · R01 · FY2023 · AI

Maternal SARS-CoV-2 infection, placenta biology, and neurodevelopmental outcomes in the offspring

$757,935

Gianluca Ursini · Lieber Institute, Inc. · R01 · FY2022 · HD

Structural interrogation of vaccine- and infection-induced B cell responses

$757,401

Goran Bajic · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · AI

SARS-CoV-2 Genomic Surveillance and Epidemiology in New Mexico

$757,295

Matthew J Campen · University Of New Mexico Health Scis Ctr · P20 · FY2021 · GM

Temporal Transcriptomics in Hospitalized COVID-19 Patients from Disparately Impacted Ancestral Groups for Therapeutic Discovery

$757,176

Douglas Jay Perkins · University Of New Mexico Health Scis Ctr · R01 · FY2023 · AI

Enriching SARS-CoV-2 sequence data in public repositories with information extracted from full text articles

$757,140

Graciela Gonzalez Hernandez · University Of Pennsylvania · R01 · FY2021 · AI

SARS-CoV-2 whole genome sequencing from large-scale campus testing and state-wide communities in NH--Center of Integrated Biomedical and Bioengineering Research (CIBBR)

$757,077

Rick H Cote · University Of New Hampshire · P20 · FY2021 · GM

COVID-19 Pandemic Mitigation, Community Economic and Social Vulnerability, and Opioid Use Disorder

$756,521

Elaine L Hill · University Of Rochester · U01 · FY2022 · DA

Molecular Basis of Allergic and Immunologic Disease

$756,246

Hans C. Oettgen · Boston Children'S Hospital · T32 · FY2023 · AI

Kinetic and structural basis for SARS-CoV-2 RNA-dependent RNA polymerase specificity and inhibition

$755,988

Kenneth Allen Johnson · University Of Texas At Austin · R01 · FY2025 · AI

Rational design of a unique vaccine for emerging pandemic coronaviruses

$755,225

Liang Qiao · Loyola University Chicago · R01 · FY2025 · AI

NCHS-CDC NHIS Taste & Smell Questionnaire Supplement

$755,000

National Institute On Deafness And Other Communication Disorders · Y01 · FY2023 · DC

Pathogenic mechanisms of chronic lung sequelae following respiratory viral infection

$754,729

Lianghui Zhang · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · HL

Temporal Transcriptomics in Hospitalized COVID-19 Patients from Disparately Impacted Ancestral Groups for Therapeutic Discovery

$754,597

Douglas Jay Perkins · University Of New Mexico Health Scis Ctr · R01 · FY2022 · AI

Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors

Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses

Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses

REstoring mental health after COVID-19 through commUnity-based Psychological services in New York City (RECOUP-NY)

Immune response to COVID-19 vaccine in HIV infected men and women

COVID-19 Mother Baby Outcomes (COMBO): brain-behavior functioning

Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm

Discovering Affective Drug Combinations for Treating Covid-19

Immunological drivers of the transition from epidemicity to endemicity of SARS-CoV-2 in a high transmission LMIC setting

Maternal SARS-CoV-2 infection, placenta biology, and neurodevelopmental outcomes in the offspring

Structural interrogation of vaccine- and infection-induced B cell responses

SARS-CoV-2 Genomic Surveillance and Epidemiology in New Mexico

Temporal Transcriptomics in Hospitalized COVID-19 Patients from Disparately Impacted Ancestral Groups for Therapeutic Discovery

Enriching SARS-CoV-2 sequence data in public repositories with information extracted from full text articles

SARS-CoV-2 whole genome sequencing from large-scale campus testing and state-wide communities in NH--Center of Integrated Biomedical and Bioengineering Research (CIBBR)

Immune memory to SARS2 in a changing landscape

Developing a Multi-epitope Pan-Coronavirus Vaccine

Deep Learning and Subtyping of Post-COVID-19 Lung Progression Phenotypes

COVID-19 Pandemic Mitigation, Community Economic and Social Vulnerability, and Opioid Use Disorder

Molecular Basis of Allergic and Immunologic Disease

Kinetic and structural basis for SARS-CoV-2 RNA-dependent RNA polymerase specificity and inhibition

Rational design of a unique vaccine for emerging pandemic coronaviruses

NCHS-CDC NHIS Taste & Smell Questionnaire Supplement

Pathogenic mechanisms of chronic lung sequelae following respiratory viral infection

Temporal Transcriptomics in Hospitalized COVID-19 Patients from Disparately Impacted Ancestral Groups for Therapeutic Discovery